Cybin Uses Psychedelic Mushroom Derivative To Tackle Depression With Improved Safety

Emerging Company Profile: Cybin’s novel approach to psilocybin therapeutics aims for better safety, shorter duration and less variability through the process of deuteration.    

Lead Candidate CYB003 Is A Deuterated Psilocybin Analog • Source: Alamy

More from Emerging Company Profiles

More from Start-Ups & SMEs